DELLA TORRE, EMANUEL
 Distribuzione geografica
Continente #
AS - Asia 3.526
NA - Nord America 2.127
EU - Europa 2.042
SA - Sud America 1.070
AF - Africa 73
OC - Oceania 37
Continente sconosciuto - Info sul continente non disponibili 2
Totale 8.877
Nazione #
US - Stati Uniti d'America 2.016
SG - Singapore 1.309
CN - Cina 1.151
BR - Brasile 881
IT - Italia 760
SE - Svezia 513
HK - Hong Kong 496
VN - Vietnam 291
RU - Federazione Russa 191
DE - Germania 151
GB - Regno Unito 96
FI - Finlandia 91
AR - Argentina 68
CA - Canada 48
IN - India 44
NL - Olanda 44
MX - Messico 43
AT - Austria 37
ID - Indonesia 35
ZA - Sudafrica 33
JP - Giappone 32
BD - Bangladesh 31
AU - Australia 30
EC - Ecuador 30
ES - Italia 30
PL - Polonia 30
TR - Turchia 26
PY - Paraguay 24
FR - Francia 21
CO - Colombia 20
IE - Irlanda 18
IQ - Iraq 18
UA - Ucraina 17
PE - Perù 16
CL - Cile 14
PK - Pakistan 13
VE - Venezuela 13
TN - Tunisia 11
IR - Iran 10
EG - Egitto 9
IL - Israele 9
CH - Svizzera 8
MA - Marocco 8
BE - Belgio 7
NZ - Nuova Zelanda 7
AE - Emirati Arabi Uniti 6
JO - Giordania 6
UZ - Uzbekistan 6
DZ - Algeria 5
HN - Honduras 5
KE - Kenya 5
KZ - Kazakistan 5
LT - Lituania 5
MY - Malesia 5
SA - Arabia Saudita 5
AL - Albania 4
DO - Repubblica Dominicana 4
GT - Guatemala 4
NP - Nepal 4
PH - Filippine 4
PT - Portogallo 4
BH - Bahrain 3
CY - Cipro 3
LB - Libano 3
LV - Lettonia 3
RO - Romania 3
TW - Taiwan 3
UY - Uruguay 3
AZ - Azerbaigian 2
CZ - Repubblica Ceca 2
EU - Europa 2
GR - Grecia 2
JM - Giamaica 2
KR - Corea 2
AM - Armenia 1
BG - Bulgaria 1
BO - Bolivia 1
BW - Botswana 1
BY - Bielorussia 1
CR - Costa Rica 1
DM - Dominica 1
GE - Georgia 1
HU - Ungheria 1
LK - Sri Lanka 1
MD - Moldavia 1
NI - Nicaragua 1
PA - Panama 1
SC - Seychelles 1
SI - Slovenia 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
Totale 8.877
Città #
Singapore 547
Hong Kong 493
Dallas 441
Shanghai 310
Beijing 237
Ashburn 208
Hefei 199
Lawrence 183
Princeton 183
New York 153
Milan 137
Ho Chi Minh City 109
Moscow 107
São Paulo 80
Helsinki 75
Hanoi 58
Los Angeles 57
Rome 57
Boardman 52
Munich 45
Rio de Janeiro 33
Nuremberg 30
London 26
Warsaw 25
Belo Horizonte 23
Denver 23
Tokyo 23
Poplar 20
Seattle 20
Dublin 18
Turin 18
Brooklyn 17
Cagliari 17
Guangzhou 17
Santa Clara 17
Atlanta 16
Vienna 16
Phoenix 15
Brasília 14
Cesano Boscone 14
Johannesburg 14
Montreal 14
Genoa 13
Manaus 13
Mexico City 13
Orem 13
Toronto 13
Frankfurt am Main 12
Mapello 12
Quito 12
Ankara 11
Bari 11
Boston 11
Florence 11
Haiphong 11
Houston 11
Porto Alegre 11
Stockholm 11
Turku 11
Bologna 10
Chennai 10
Curitiba 10
Guarulhos 10
Pavia 10
Pescara 10
Rovigo 10
San Francisco 10
Wollongong 10
Xi'an 10
Bergamo 9
Galliate 9
Jiaxing 9
Pune 9
Salvador 9
Amsterdam 8
Asunción 8
Baghdad 8
Biên Hòa 8
Brisbane 8
Campinas 8
Cape Town 8
Da Nang 8
Falkenstein 8
Guayaquil 8
Jakarta 8
Naples 8
Sundbyberg 8
Vaprio d'Adda 8
Verona 8
Alessandria 7
Bauru 7
Borås 7
Breda 7
Calasparra 7
Caruaru 7
Caxias do Sul 7
Lima 7
Melbourne 7
Mugnano di Napoli 7
Reston 7
Totale 4.703
Nome #
PACHIMENINGITE IPERTROFICA IGG4-CORRELATA: DIAGNOSI E RISPOSTA TERAPEUTICA 318
Outcomes of non-invasive ventilation as the ceiling of treatment in patients with COVID-19 178
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors 131
A subset of CD4+CD8α- Cytotoxic T cells is expanded in patients with IgG4-Related type 1 autoimmune pancreatitis and decreases with glucocorticoid treatment 113
Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study 107
IgG4-related disease in Italy: clinical features and outcomes of a large cohort of patients 101
ABS0671 IgG4-RELATED DISEASE IN OVERLAP WITH IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE: CLINICAL-PATHOLOGICAL CHARACTERISTICS AND THERAPEUTIC IMPLICATIONS OF AN ORPHAN DISEASE 95
High Risk of Secondary Infections Following Thrombotic Complications in Patients With COVID-19 94
A CD8α− Subset of CD4+SLAMF7+ Cytotoxic T Cells Is Expanded in Patients With IgG4-Related Disease and Decreases Following Glucocorticoid Treatment 91
Dupilumab as a potential steroid-sparing treatment for IgG4-related disease. 84
Efficacy of a rational algorithm to assess allergy risk in patients receiving the BNT162b2 vaccine 84
Quantitative measurement of 18F-FDG PET/CT uptake reflects the expansion of circulating plasmablasts in IgG4-related disease 80
A cd8 alpha-negative subset of cd4+slamf7+ cytotoxic t cells is expanded in patients with igg4-related disease and decreases following glucocorticoid treatment 78
ASSOCIAZIONE TRA MALATTIA IGG4-CORRELATA E IMMUNOTERAPIA ALLERGENE-SPECIFICA. STUDIO EPIDEMIOLOGICO DI UN CENTRO DI RIFERIMENTO ITALIANO. 76
Advances in the diagnosis and management of IgG4 related disease. 74
Analisi delle sottopopolazioni T linfocitarie su sangue periferico dei pazienti affetti da malattia IgG4 correlata: aspetti patogenetici e risposta alla terapia con rituximab 72
IgG4-related pachymeningitis: evidence of intrathecal IgG4 on cerebrospinal fluid analysis. 71
La misurazione quantitativa dell’uptake di 18F-FDG in TC/PET riflette l’espansione dei plasmablasti circolanti nella malattia IgG4 correlata 70
B lymphocytes directly contribute to tissue fibrosis in patients with IgG4-related disease. 70
B lymphocytes directly contribute to tissue fibrosis in IgG4-Related Disease 68
IMMUNOTERAPIA SPECIFICA E MALATTIA IgG4-CORRELATA: STUDIO EPIDEMIOLOGICO DI UN CENTRO DI RIFERIMENTO ITALIANO 68
Efficacy and safety of rituximab biosimilar (CT-P10) in IgG4-related disease: an observational prospective open-label cohort study 66
CLINICAL PHENOTYPES OF IGG4- RELATED DISEASE REFLECT DIFFERENCES IN EPIDEMIOLOGICAL FEATURES, SEROLOGICAL FINDINGS,AND PROGNOSTIC OUTCOMES 66
Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation 64
IgG4-Related Midline Destructive Lesion: Expanding the spectrum of organ involvement in IgG4-related disease 64
Interleukin 1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study 63
B lymphocytes directly contribute to tissue fibrosis in IgG4-Related Disease 62
B cells orchestrate tissue fibrosis in IgG4-Related Disease 62
B lymphocytes contribute to stromal reaction in pancreatic ductal adenocarcinoma 61
ALLERGIC PROFILE AND ALLERGENSPECIFIC IMMUNOTHERAPY IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA): A SINGLE CENTER OBSERVATIONAL STUDY 61
CLINICAL PHENOTYPES OF IGG4-RELATED DISEASE REFLECT DIFFERENCES IN EPIDEMIOLOGICAL, IMMUNOLOGICAL AND PROGNOSTIC FEATURES 61
Clinical phenotypes of IgG4-related disease reflect different prognostic outcomes 60
ANTIAPOPTOTIC AND IMMUNOMODULATORY EFFECTS OF INTERLEUKIN 7 IN AN EX VIVO MODEL OF HUMAN LYMPHOID TISSUE 60
Are atopy and eosinophilic bronchial inflammation associated with relapsing forms of chronic rhinosinusitis with nasal polyps? 59
A unique case of IgG4-related pachymeningitis treated with intrathecal rituximab 59
CLINICAL MANIFESTATIONS OF IGG4-RELATED DISEASE ONSET REQUIRE ADMISSION TO THE EMERGENCY DEPARTMENT IN THE MAJORITY OF CASES. EXPERIENCE FROM A SINGLE ITALIAN REFERRAL CENTRE 59
Urgent manifestations of immunoglobulin G4-related disease 58
Antineutrophil cytoplasmic antibody positivity in IgG4-related disease: A case report and review of the literature. 58
B LYMPHOCYTES DIRECTLY CONTRIBUTE TO TISSUE FIBROSIS IN IGG4-RELATED DISEASE 58
Incidence of endocrine and exocrine insufficiency in patients with autoimmune pancreatitis at diagnosis and after treatment: a systematic review and meta-analysis 57
Salivary Gland Disease in IgG4-Related Disease is Associated with Allergic Conditions 57
"How I manage" IgG4-Related Disease 57
Differential EUS findings in focal type 1 autoimmune pancreatitis and pancreatic cancer: A proof-of-concept study 56
Impact of sarilumab on mechanical ventilation in patients with COVID-19. Response to: 'Correspondence on: 'Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation-an open-label cohort study' by Della-Torre et al ' by Cheng and Zhang 54
Systemic lupus erythematosus and COVID-19: what we know so far 54
Clinical and dermoscopic features of Castelman's disease: insights from an emblematic case 53
Targeting IL-1, IL-6 or GM-CSF in COVID-19. Response to: 'More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia' by Ferraccioli 52
LONG-TERM EFFICACY OF RITUXIMAB MAINTENANCE THERAPY FOR IGG4- RELATED DISEASE RITUXIMAB MAINTENANCE THERAPY IN IGG4-RELATED DISEASE 52
IgG4-RELATED DISEASE PRESENTATION REQUIRES ADMISSION TO THE EMERGENCY DEPARTMENT IN THE MAJORITY OF CASES 52
Atypical presentation of Churg-Strauss syndrome or an undescribed hypereosinophilic disease? 51
INCREASE OF CIRCULATING MEMORY B CELLS AFTER GLUCOCORTICOID-INDUCED REMISSION PREDICTS IGG4-RELATED DISEASE RELAPSE 51
Artrite reumatoide. Dottore mi spieghi meglio 51
Clinical features and outcomes of COVID-19 in patients with IgG4-related disease: A European multi-centre study 50
Cerebrospinal fluid analysis in immunoglobulin G4-related hypertrophic pachymeningitis 50
EFFECTS OF GLUCOCORTICOIDS AND METHOTREXATE-BASED THERAPEUTIC REGIMENS ON B CELL SUBPOPULATIONS IN PATIENTS WITH IGG4-RELATED DISEASE 50
Malattia sistemica e colangiopatia IgG4-relata 50
An International, Multi-Specialty Validation Study of the IgG4-Related Disease Responder Index 50
Correspondence on 'Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort' 49
INFLAMMATORY ACTIVITY OF IgG4-RELATED DISEASE LESIONS ASSESSED BY QUANTITATIVE POSITRON EMISSION TOMOGRAPHY CORRELATES WITH CIRCULATING PLASMABLASTS LEVELS 49
MAVRILIMUMAB IMPROVES OUTCOMES IN SEVERE COVID-19 PNEUMONIA AND SYSTEMIC HYPERINFLAMMATION 49
25. Epinephrine autoinjector prescription in food-allergic adults: symptom-based only or allergen-based also? An Italian multi-centre study. 49
Atopia e malattia IgG4-correlata: relazione casuale o causale? 49
EUS-guided ablation with the HybridTherm Probe as second-line treatment in patients with locally advanced pancreatic ductal adenocarcinoma: A case-control study 48
Intrathecal rituximab for IgG4-related hypertrophic pachymeningitis 48
IDENTIFICAZIONE DI UNA SOTTOPOPOLAZIONE CD8- DI LINFOCITI CD4 CITOTOSSICI ESPANSA NEI PAZIENTI CON MALATTIA IGG4-CORRELATA E RESPONSIVA ALLA TERAPIA CON GLUCOCORTICOIDI 48
Effects Of Glucocorticoids On B Cell Subpopulations In Patients With IgG4-Related type I autoimmune pancreatitis 48
EpidemAAITO: features of food allergy in Italian adults attending allergy clinics: a multi-centre study 48
European Guideline on IgG4-related digestive disease - UEG and SGF evidence-based recommendations. 48
IgG4-Related diseases 48
Deconstructing IgG4-related disease involvement of midline structures: Comparison to common mimickers. 47
METHOTREXATE AS INDUCTION OF REMISSION THERAPY FOR LOCALIZED MANIFESTATIONS OF IGG4-RELATED DISEASE 47
Methotrexate as induction of remission therapy for localized manifestations of IgG4-Related Disease. 47
MALATTIA IGG4-CORRELATA: ESPERIENZA QUINQUENNALE MONOCENTRICA SU UNA CORTE ITALIANA DI 150 PAZIENTI (2013 - 2018) 46
Identification of Galectin-3 as an autoantigen in IgG4-Related Disease using monoclonal antibodies from dominantly expanded patient-derived plasmablasts 45
IDENTIFICATION OF GALECTIN-3 AS AN AUTO-ANTIGEN IN IGG4-RELATED DISEASE USING MONOCLONAL ANTIBODIES FROM DOMINANTLY EXPANDED PATIENT-DERIVED PLASMABLASTS 45
Side effects from polydioxanone 45
Utility of the “2019 ACR/EULAR classification criteria” for the management of patients with IgG4-related disease 44
Lymphadenopathy in the rheumatology practice: a pragmatic approach 44
B LYMPHOCYTES DIRECTLY CONTRIBUTE TO TISSUE FIBROSIS IN IGG4-RELATED DISEASE 44
EFFICACY OF LONG-TERM TREATMENT WITH BIOLOGIC AGENTS IN REFRACTORY ADULT ONSET STILL’S DISEASE: A SINGLE CENTRE EXPERIENCE ON 16 PATIENTS 44
Clonal Expansion of a Speci c Subset of Cytotoxic CD4+T Cells and Tissue Apoptosis in Patients with IgG4-related Disease 44
IgG4-related hypertrophic pachymeningitis: clinical features, diagnostic criteria, and treatment. 44
B LYMPHOCYTES DIRECTLY CONTRIBUTE TO TISSUE FIBROSIS IN IGG4-RELATED AUTOIMMUNE PANCREATITIS 44
Cannabaceae pollen in the atmosphere of Brianza, Northen Italy 44
EFFETTI DEL PREDNISONE SULLE SOTTOPOPOLAZIONI B LINFOCITARIE NEI PAZIENTI CON MALATTIA IgG4-CORRELATA 43
LA DEPLEZIONE DI CELLULE B RIDUCE IL GRADO DI FIBROSI SISTEMICA E L’ATTIVAZIONE DEI MIOFIBROBLASTI TISSUTALI IN CORSO DI MALATTIA IGG4-CORRELATA 43
HYPERSENSITIVITY REACTIONS TO LOW MOLECULAR WEIGHT HEPARIN IN A PREGNANT WOMAN 43
Increase of circulating memory B cells after glucocorticoid-induced remission identifies patients at risk of IgG4-related disease relapse 42
Clonally Expanded CD4+ Cytotoxic T Cells, Endothelial Cell Apoptosis and the Pathogenesis of Early Systemic Sclerosis 42
MERTK AND THE RESOLUTION OF INFLAMMATION IN IGG4-RELATED DISEASE 42
IgG4-­RD Cases and Mimickers: A Summary 42
In vivo tests with "Tahini" sauce: new allergenic source to evaluate IgE-mediated hypersensitivity to sesame. 42
CLONAL EXPANSION OF CD4+ CYTOTOXIC T LYMPHOCYTES IN IGG4-RELATED DISEASE 41
CIRCULATING PLASMABLASTS LEVELS REFLECT INFLAMMATORY ACTIVITY IN IGG4-RELATED DISEASE LESIONS AS ASSESSED BY QUANTITATIVE POSITRON EMISSION TOMOGRAPHY 41
Circulating TH2 memory cells in IgG4-related disease are restricted to a defined subset of subjects with atopy 41
Optimal management of DRESS syndrome in course of infectious endocarditis. 41
Malattie autoinfiammatorie e altre malattie immunomediate a patogenesi incerta 41
IGG4 RELATED HYPERTROPHIC PACHYMENINGITIS: DIAGNOSTIC APPROACH AND THERAPEUTIC OUTCOMES 40
B-cell depletion attenuates serological biomarkers of fibrosis and myofibroblast activation in IgG4-related disease. 40
Long-term efficacy of maintenance therapy with Rituximab for IgG4-related disease 39
Totale 6.089
Categoria #
all - tutte 69.949
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 69.949


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202119 0 0 0 0 0 8 4 1 1 1 3 1
2021/2022348 1 0 151 33 6 22 14 23 34 21 23 20
2022/20231.129 455 213 66 8 32 115 62 57 59 14 22 26
2023/2024920 30 62 81 82 49 167 42 89 5 42 92 179
2024/20252.858 351 84 81 76 97 222 352 300 550 329 177 239
2025/20263.837 631 790 689 1.061 631 35 0 0 0 0 0 0
Totale 9.141